Trial reportEuropean journal of nuclear medicine and molecular imaging2021
Patterns of disease detection using [
Trial report in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Detection of Biochemically Recurrent Prostate Cancer with [Tomography (Ann Arbor, Mich.) · 2023Pooled it
- The Diagnostic Role ofFrontiers in oncology · 2021Pooled it
- Biochemical failure after radical prostatectomy with PSA ≤ 1 ng/mL: prediction of PSMA-positive metastatic disease.Annals of nuclear medicine · 2026Article
- Global research landscape of PSMA-targeted radiopharmaceuticals: a two-decade multidimensional bibliometric analysis.Japanese journal of radiology · 2026Article
- Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment.Cancers · 2024Review
- Investigating PSMA-PET/CT to resolve prostate MRI PIRADS4-5 and negative biopsy discordance.World journal of urology · 2023Article
- Necessity of Pelvic Lymph Node Irradiation in Patients with Recurrent Prostate Cancer after Radical Prostatectomy in the PSMA PET/CT Era: A Narrative Review.Biomedicines · 2022Review
- Article
- Changes in Management AfterJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Pathological predictors ofBJU international · 2022Article
- Piflufolastat F 18: Diagnostic First Approval.Molecular diagnosis & therapy · 2021Review
- Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProstate-specific membrane antigen (PSMA) PET/CT is increasingly used in patients with biochemical recurrence post prostatectomy to detect local recurrence and metastatic disease at low PSA levels. The aim of this study was to assess patterns of disease detection, predictive factors and safety using [
methodsWe conducted a prospective trial recruiting 100 patients with detectable PSA post prostatectomy (PSA 0.2-2.0 ng/mL) and referred for salvage radiotherapy from August 2018 to July 2020. All patients underwent a PSMA PET/CT using the [
resultsOf 100 patients recruited, 98 were suitable for analysis with a median PSA of 0.32 ng/mL. [
conclusions[
trial registrationAustralian New Zealand Clinical Trials Registry Number: ACTRN12618001530213 ( http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=375932&isReview=true ).
Indexed as
Identifiers
33852051What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.